Answer
Abecma (idecabtagene vicleucel) has been associated with aphasia, encephalopathy and immune effector cell-associated neurotoxicity syndrome (ICANS), which may be severe or life-threatening, and delayed-onset Grade 3 parkinsonism.
Sources for this answer
- Abecma 260 - 500 x 10^6 cells dispersion for infusionBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 3Document updated
Sources checked